<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="3f726b10-ef7b-47d6-96c9-e1a7ee5461d9"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use CIPROFLOXACIN OTIC SOLUTION safely and effectively. See full prescribing information for CIPROFLOXACIN OTIC SOLUTION <br/>
      <br/> CIPROFLOXACIN otic solution<br/> Initial U.S. Approval: 1987</title>
   <effectiveTime value="20250415"/>
   <setId root="51dde3f2-adb1-4ed8-83c6-1f63723a2529"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="113290444" root="1.3.6.1.4.1.519.1"/>
            <name>Genus Lifesciences</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="c66507cc-725b-405d-90dc-325ceb97ef17"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20241231"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="64950-381" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Ciprofloxacin Otic</name>
                        <formCode code="C60992" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION/ DROPS"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Ciprofloxacin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="0.5" unit="mg"/>
                              <denominator value="0.25" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="5E8K9I0O4U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ciprofloxacin</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="5E8K9I0O4U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Ciprofloxacin</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PDC6A3C0OX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="33X04XA5AT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTIC ACID, UNSPECIFIED FORM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="0.25" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="14" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="64950-381-14" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20241201"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA217887" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20241201"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38192" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="AURICULAR (OTIC)"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="fa140513-4a6a-485d-a9af-61ce1b8fbc9e"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Ciprofloxacin otic solution, 0.2% is a quinolone antimicrobial indicated for the treatment of acute otitis externa due to susceptible isolates of <content styleCode="italics">Pseudomonas aeruginosa or Staphylococcus aureus</content>.</paragraph>
               </text>
               <effectiveTime value="20241231"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Ciprofloxacin otic solution, 0.2% is a quinolone antimicrobial indicated for the treatment of acute otitis externa due to susceptible isolates of <content styleCode="italics">Pseudomonas aeruginosa</content> or <content styleCode="italics">Staphylococcus aureus</content>. (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="ca72fd9d-9313-4c6f-90c7-3d0073f15373"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>The contents of one single-dose container (deliverable volume: 0.25 mL) should be instilled into the affected ear twice daily (approximately 12 hours apart) for 7 days.</paragraph>
                  <paragraph>Wash hands before use. The solution should be warmed, by holding the container in the hands for at least 1 minute, to minimize the dizziness that may result from the instillation of a cold solution into the ear canal. The patient should lie with the affected ear upward and then the solution should be instilled. This position should be maintained for at least 1 minute to facilitate penetration of the drops into the ear. Repeat, if necessary, for the opposite ear. Discard unused portion.</paragraph>
               </text>
               <effectiveTime value="20241231"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Contents of one single-dose container should be instilled into the affected ear twice daily (approximately 12 hours apart) for 7 days. (<linkHtml href="#S2">2</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="9a76e9ff-5061-444a-ab4b-631bed45a3bf"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Ciprofloxacin otic solution, 0.2% is a sterile, preservative-free, otic solution of ciprofloxacin hydrochloride equivalent to 0.2 % ciprofloxacin (0.5 mg in 0.25 mL) in each single-dose container.</paragraph>
               </text>
               <effectiveTime value="20241231"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Ciprofloxacin otic solution, 0.2% is a sterile, preservative-free otic solution of ciprofloxacin hydrochloride equivalent to 0.2 % ciprofloxacin (0.5 mg in 0.25 mL) in each single-dose container. (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="17f4cadb-e67c-4075-b0a4-68f8a62c7c0e"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Ciprofloxacin otic solution, 0.2% is contraindicated in persons with a history of hypersensitivity to ciprofloxacin.</paragraph>
               </text>
               <effectiveTime value="20241231"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>History of hypersensitivity to ciprofloxacin. (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="82c53065-dabf-4925-ae0b-47b09b05fc8c"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20241231"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Ciprofloxacin otic solution, 0.2% is for otic use only. (<linkHtml href="#S5.1">5.1</linkHtml>)</paragraph>
                        <paragraph>Hypersensitivity: discontinue at the first appearance of a skin rash or any other sign of hypersensitivity. (<linkHtml href="#S5.2">5.2</linkHtml>)</paragraph>
                        <paragraph>Use of ciprofloxacin otic solution, 0.2% may result in overgrowth of nonsusceptible organisms. (<linkHtml href="#S5.3">5.3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="41c26eae-6b98-46b0-a045-cf6f98459b81"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1  Otic Use Only</title>
                     <text>
                        <paragraph>Ciprofloxacin otic solution, 0.2% is for otic use only. It should not be used for injection, for inhalation or for topical ophthalmic use.</paragraph>
                     </text>
                     <effectiveTime value="20241231"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="9132a215-d3f2-4beb-8b45-f6659c45cfbc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2  Hypersensitivity</title>
                     <text>
                        <paragraph>Ciprofloxacin otic solution, 0.2% should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity.</paragraph>
                     </text>
                     <effectiveTime value="20241231"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="ce970e16-e1ed-4eec-ae46-048e725225bf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3  Growth of Rsistant Organisms with Prolonged Use</title>
                     <text>
                        <paragraph>As with other anti-infectives, use of ciprofloxacin otic solution, 0.2% may result in overgrowth of nonsusceptible organisms, including yeast and fungi. If super-infection occurs, discontinue use and institute alternative therapy.</paragraph>
                     </text>
                     <effectiveTime value="20241231"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="706e8118-edba-4f72-a949-4a5cdfe034ae"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4  Lack of Clinical Response</title>
                     <text>
                        <paragraph>If the infection is not improved after one week of therapy, cultures may help guide further treatment.</paragraph>
                     </text>
                     <effectiveTime value="20241231"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="c1077aa3-3bd0-44d9-b4e6-fb8e11414fb9"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Because clinical studies are conducted under widely varying conditions, adverse drug reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.</paragraph>
                  <paragraph>In a randomized, active-controlled clinical trial, approximately 300 patients with clinical signs and symptoms of otitis externa were treated with ciprofloxacin otic solution, 0.2%. The most frequently reported adverse reactions were application site pain, ear pruritus, fungal ear superinfection, and headache, each reported in approximately 2-3% of patients.</paragraph>
               </text>
               <effectiveTime value="20241231"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions reported in 2-3% of patients treated with ciprofloxacin otic solution, 0.2% were application site pain, ear pruritus, fungal ear superinfection and headache. (<linkHtml href="#S6">6</linkHtml>)</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Allucent at 1-866-511-6754 or FDA at 1-800-FDA-1088 or <content styleCode="italics">www.fda.gov/medwatch</content>. (<linkHtml href="#S6">6</linkHtml>)</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="b6b41647-8a55-480c-a87e-db8140a240df"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20241231"/>
               <component>
                  <section ID="S8.1">
                     <id root="d189cfab-94d3-42fb-a85a-9942c1a6cba3"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20241231"/>
                     <component>
                        <section>
                           <id root="22b1a0ba-1cef-4a3b-ba2b-027caf07d5f2"/>
                           <code code="34077-8" codeSystem="2.16.840.1.113883.6.1" displayName="TERATOGENIC EFFECTS SECTION"/>
                           <text>
                              <paragraph>Pregnancy Category C.</paragraph>
                              <paragraph>Reproduction studies have been performed in rats and mice using oral doses of up to 100 mg/kg and intravenous (IV) doses up to 30 mg/kg and have revealed no evidence of harm to the fetus as a result of ciprofloxacin. In rabbits, ciprofloxacin (30 and 100 mg/kg orally) produced gastrointestinal disturbances resulting in maternal weight loss and an increased incidence of abortion, but no teratogenicity was observed at either dose. After intravenous administration of doses up to 20 mg/kg, no maternal toxicity was produced in the rabbit, and no embryotoxicity or teratogenicity was observed.</paragraph>
                              <paragraph>Animal reproduction studies have not been conducted with ciprofloxacin otic solution, 0.2%. No adequate and well controlled studies have been performed in pregnant women. Caution should be exercised when ciprofloxacin otic solution, 0.2% is used by a pregnant woman.</paragraph>
                           </text>
                           <effectiveTime value="20241231"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="7cbacc01-80a7-4475-a955-57a55e211af5"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.3 Nursing Mothers</title>
                     <text>
                        <paragraph>Ciprofloxacin is excreted in human milk with systemic use. It is not known whether ciprofloxacin is excreted in human milk following otic use. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. </paragraph>
                     </text>
                     <effectiveTime value="20241231"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="66e7669b-720b-45bd-a330-a92a8f2a7f57"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of ciprofloxacin otic solution, 0.2% in infants below one year of age have not been established. The efficacy of ciprofloxacin otic solution, 0.2% in treating otitis externa in pediatric patients one year or older has been demonstrated in controlled clinical trials (see <linkHtml href="#S14">Section 14 Clinical Studies</linkHtml>).</paragraph>
                        <paragraph>There is no evidence that the otic administration of quinolones has any effect on weight bearing joints, even though systemic administration of some quinolones has been shown to cause arthropathy in immature animals.</paragraph>
                     </text>
                     <effectiveTime value="20241231"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="99b6a5fe-3108-4ed0-a824-1e770bb8d540"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>No overall differences in safety and effectiveness have been observed between elderly and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20241231"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="49cf7624-6d03-42fb-b62b-54938fa78ecd"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Ciprofloxacin otic solution, 0.2% contains the synthetic antimicrobial agent ciprofloxacin hydrochloride. Ciprofloxacin otic solution, 0.2% is a sterile, preservative-free solution for otic use. Each single-dose container of ciprofloxacin otic solution, 0.2% delivers 0.25 mL of solution equivalent to 0.5 mg of ciprofloxacin. The inactive ingredients are povidone, glycerin, and water for injection. Sodium hydroxide and/or lactic acid may be added to adjust pH.</paragraph>
                  <paragraph>Ciprofloxacin, a fluroquinolone is available as the monohydrochloride, monohydrate salt of 1cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid. Its molecular formula is C<sub>17</sub>H<sub>18</sub>FN<sub>3</sub>O<sub>3</sub>∙HCl∙H<sub>2</sub>O, and molecular weight is 385.82.</paragraph>
                  <paragraph>The chemical structure of ciprofloxacin hydrochloride is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
               </text>
               <effectiveTime value="20241231"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="cipro-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="38c4ec02-9321-411b-b070-e28d43b52b55"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20241231"/>
               <component>
                  <section ID="S12.1">
                     <id root="8519a1c5-c100-4891-94c3-0c8b10bc8b72"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Ciprofloxacin is a fluoroquinolone antimicrobial (see <linkHtml href="#S12.4">12.4 Clinical Pharmacology, Microbiology</linkHtml>).</paragraph>
                     </text>
                     <effectiveTime value="20241231"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="71047849-7aa6-4ffa-8d90-5e0d5c9be8fe"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The plasma concentrations of ciprofloxacin were not measured following administration of 0.25 mL ciprofloxacin otic solution, 0.2% (total dose: 0.5 mg ciprofloxacin). However, the maximum plasma concentration of ciprofloxacin is anticipated to be less than 5 ng/mL.</paragraph>
                     </text>
                     <effectiveTime value="20241231"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.4">
                     <id root="e3001ccf-aeb3-4635-9259-a8e0fde37525"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.4 Microbiology</title>
                     <text>
                        <paragraph>The bactericidal action of ciprofloxacin results from interference with the enzyme DNA gyrase, which is needed for the synthesis of bacterial DNA.</paragraph>
                        <paragraph>Bacterial resistance to quinolones can develop through chromosomally- or plasmid-mediated mechanisms.</paragraph>
                        <paragraph>The mechanism of action of fluoroquinolones, including ciprofloxacin, is different from that of macrolides. Therefore, ciprofloxacin may be active against pathogens that are resistant to these antibiotics, and these antibiotics may be active against pathogens that are resistant to ciprofloxacin. <content styleCode="italics">In vitro</content> studies demonstrated cross-resistance between ciprofloxacin and some fluoroquinolones.</paragraph>
                        <paragraph>Ciprofloxacin has been shown to be active against most isolates of the following bacteria, both <content styleCode="italics">in vitro</content> and in clinical infections of acute otitis externa as described in Section 1 Indications and Usage.</paragraph>
                        <table width="50%" styleCode="Noautorules">
                           <col width="50%" align="left" valign="top"/>
                           <col width="50%" align="left" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>
                                    <content styleCode="italics">Staphylococcus aureus</content>
                                 </td>
                                 <td>
                                    <content styleCode="italics">Pseudomonas aeruginosa</content>.</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20241231"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="5aeaa56a-7dc8-4c2c-9cbb-671d509d1917"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20241231"/>
               <component>
                  <section ID="S13.1">
                     <id root="7f1ec79b-50a5-4849-9d86-a6854a1d9556"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility</title>
                     <text>
                        <paragraph>Long-term carcinogenicity studies in mice and rats have been completed for ciprofloxacin. After daily oral doses of 750 mg/kg (mice) and 250 mg/kg (rats) were administered for up to 2 years, there was no evidence that ciprofloxacin had any carcinogenic or tumorigenic effects in these species. No long-term studies of ciprofloxacin otic solution, 0.2% have been performed to evaluate carcinogenic potential.</paragraph>
                        <paragraph>Eight <content styleCode="italics">in vitro</content> mutagenicity tests have been conducted with ciprofloxacin, and the test results are listed below:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="italics">Salmonella/</content>Microsome Test (Negative)</item>
                           <item>
                              <content styleCode="italics">Escherichia coli</content> DNA Repair Assay (Negative)</item>
                           <item>Mouse Lymphoma Cell Forward Mutation Assay (Positive)</item>
                           <item>Chinese Hamster V79 Cell HGPRT Test (Negative)</item>
                           <item>Syrian Hamster Embryo Cell Transformation Assay (Negative)</item>
                           <item>
                              <content styleCode="italics">Saccharomyces cerevisiae</content> Point Mutation Assay (Negative)</item>
                           <item>
                              <content styleCode="italics">Saccharomyces cerevisiae</content> Mitotic Crossover and Gene Conversion Assay (Negative)</item>
                           <item>Rat Hepatocyte DNA Repair Assay (Positive).</item>
                        </list>
                        <paragraph>Two of the 8 <content styleCode="italics">in vitro</content> tests were positive, but results of the following 3 <content styleCode="italics">in vivo</content> test systems gave negative results:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Rat Hepatocyte DNA Repair Assay</item>
                           <item>Micronucleus Test (Mice)</item>
                           <item>Dominant Lethal Test (Mice).</item>
                        </list>
                        <paragraph>Fertility studies performed in rats at oral doses of ciprofloxacin up to 100 mg/kg/day revealed no evidence of impairment. This would be over 100 times the maximum recommended clinical dose of ototopical ciprofloxacin based upon body surface area, assuming total absorption of ciprofloxacin from the ear of a patient treated with ciprofloxacin otic solution, 0.2% twice per day.</paragraph>
                     </text>
                     <effectiveTime value="20241231"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="f160d042-2fdb-4da1-b833-d3737aef90b0"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>In a randomized, multi-center, evaluator-blinded study of patients with acute otitis externa, patients were treated with either ciprofloxacin otic solution, 0.2% twice daily or neomycin and polymyxin B sulfates and hydrocortisone otic solution (PNH) three times daily for 7 days.</paragraph>
                  <paragraph>In the per protocol population, clinical cure was achieved at the end of a 7-day treatment in 70% (173/247) for the ciprofloxacin otic solution, 0.2% treated group versus 60% (147/243) for the control treated group.</paragraph>
               </text>
               <effectiveTime value="20241231"/>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="ee5fc958-6fa0-4107-9dc4-d59dfe1f9377"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Ciprofloxacin otic solution, 0.2% is a clear, colorless, sterile, preservative-free solution. Ciprofloxacin otic solution, 0.2% is supplied as a 0.2% otic solution in a low-density polyethylene (LDPE) single-dose container. Each single-dose container delivers 0.25 mL of solution equivalent to 0.5 mg of ciprofloxacin; 14 single-dose containers are packaged in a foil overwrap pouch in a carton (NDC 64950-381-14).</paragraph>
               </text>
               <effectiveTime value="20241231"/>
               <component>
                  <section>
                     <id root="8e534042-f2f8-43a8-80fd-5897d0281ee7"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Store at 15°C to 25°C (59°F to 77°F). Discard used containers. Store unused containers in pouch to protect from light.</paragraph>
                     </text>
                     <effectiveTime value="20241231"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="7993dd1a-2821-417f-826f-9c567d0ce44e"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <effectiveTime value="20241231"/>
               <component>
                  <section ID="S17.1">
                     <id root="65666fdd-8476-46cf-bcbc-d683c3d9feb7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.1	Directions for Use</title>
                     <text>
                        <paragraph>Patients should be advised that ciprofloxacin otic solution, 0.2% is for otic use only. It is not for ophthalmic or inhalation use. It is not for injection.</paragraph>
                        <paragraph>Ciprofloxacin otic solution, 0.2% should be given 2 times each day (about 12 hours apart) in each infected ear.</paragraph>
                        <paragraph>Ciprofloxacin otic solution, 0.2% should be used for as long as it is prescribed, even if the symptoms improve. The patient should be advised to follow these directions while on ciprofloxacin otic solution, 0.2%: Wash their hands before use.</paragraph>
                        <renderMultiMedia referencedObject="MM2"/>
                        <paragraph>Warm the container in their hands for at least one minute prior to use to minimize dizziness that may result from the instillation of a cold solution into the ear canal. Twist off and discard top of container.</paragraph>
                        <renderMultiMedia referencedObject="MM3"/>
                        <paragraph>Lie with the affected ear upward and then instill the contents of one container into the ear. Maintain this position for at least one minute to facilitate penetration of the drops into the ear.</paragraph>
                        <renderMultiMedia referencedObject="MM4"/>
                        <list listType="unordered" styleCode="disc">
                           <item>Repeat, if necessary, for the opposite ear.</item>
                           <item>Discard used container.</item>
                           <item>Store unused containers in pouch to protect from light.</item>
                        </list>
                     </text>
                     <effectiveTime value="20241231"/>
                     <component>
                        <observationMedia ID="MM2">
                           <text>Image</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="cipro-02.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM3">
                           <text>Image</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="cipro-03.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM4">
                           <text>Image</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="cipro-04.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S17.2">
                     <id root="da62643b-6590-4803-9dc2-48f525326f16"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.2 Hypersensitivity </title>
                     <text>
                        <paragraph>Patients should be advised to immediately discontinue ciprofloxacin otic solution, 0.2% at the first appearance of a skin rash or any other sign of hypersensitivity [see <linkHtml href="#S5.1">Section 5.1 Warnings and Precautions</linkHtml>].</paragraph>
                     </text>
                     <effectiveTime value="20241231"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="3b225dec-ab18-4038-9cc6-db9e2b955c97"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Ciprofloxacin otic solution, 0.2% is Distributed by:<br/>
                     <content styleCode="bold">Genus Lifesciences Inc.</content>
                     <br/>Allentown, PA 18102</paragraph>
               </text>
               <effectiveTime value="20241231"/>
            </section>
         </component>
         <component>
            <section>
               <id root="1f807246-b475-47c3-bdd9-df563b174bbc"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 14 Vial Carton</title>
               <text>
                  <paragraph>NDC 64950-381-14</paragraph>
                  <paragraph>Sterile<br/>Preservative-Free</paragraph>
                  <paragraph>Ciprofloxacin Otic<br/>Solution, 0.2%</paragraph>
                  <paragraph>Containers not for<br/>individual sale.</paragraph>
                  <paragraph>Discard used containers.<br/>Store at 15°C to 25°C (59°F to 77°F).<br/>Store unused containers in pouch to<br/>protect from light.</paragraph>
                  <paragraph>Contents: 14 single-dose containers,<br/>0.25 mL each (deliverable volume)</paragraph>
                  <paragraph>OTIC USE<br/>USE IN EARS<br/>ONLY</paragraph>
                  <paragraph>Manufactured for:<br/>Genus Lifesciences Inc.<br/>Allentown, PA 18102</paragraph>
                  <paragraph>Manufactured by:<br/>Holopack Verpackungstechnik<br/>GmbH Sulzbach-Laufen,<br/>Germany 74429<br/>Origin Germany<br/>Rev 12/2024</paragraph>
                  <paragraph>Genus <br/>Lifesciences Inc.</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <renderMultiMedia referencedObject="MM5"/>
               </text>
               <effectiveTime value="20241231"/>
               <component>
                  <observationMedia ID="MM5">
                     <text>Principal Display Panel - 14 Vial Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="cipro-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>